Company profile
UK company 12966888, incorporated on 22 October 2020.
The London School of Hygiene & Tropical Medicine | LSHTM
Arkvax Limited is a UK company with status active founded in 2020 based in London.
Company number 12966888
Reference milestones and recent Companies House filing stream events.
Company registered at Companies House
ArkVax develops vaccines for animals through glycoengineering.
At the LSHTM I am the co-director of a newly established company, ArkVax, aiming to utilise the expertise obtained whilst working in the fields of glycobiology and glycoengineering. The company aims to produce novel glycan based prototype vaccines against bacterial animal pathogens. An examplar vaccine family missing in the farming industry are glycoconjugate vaccines. These have been utilised for years in humans and saved millions of lives but despite sporadic proof of principle projects in animals, none are currently available to protect livestock against disease. The major factor in this is cost. ArkVax aims to harness all of the latest glycoengineering developments in the fiedl of bacterial glycobiology in order to modify currently licensed live attenuated vaccines as well as generate novel vaccine combinations to assemble next generation multivalent glycocan based vaccines .
A new spin out company that derived from ArcVax was formed on 20/10/2020. The company won a competitive accelerator award and currently has labs at Babraham Research Park, Cambs and focuses on using novel glycoengineering technology for the development of glycoconjugate vaccines with a particular emphasis on animal vaccines
N/A as the company is currently in the process of securing contracts and funding
The focus of the company is the development of multicomponent poultry, pig and ruminant vaccines. The business is supported contract research for vaccine candidate from established vet vaccine companies and further funding is currently being sought from a range of investors.
